Eisaburo Sueoka Selected Research

Tea

2/2018	Cancer Prevention with Green Tea and Its Principal Constituent, EGCG: from Early Investigations to Current Focus on Human Cancer Stem Cells.
12/2017	Human cancer stem cells are a target for cancer prevention using (-)-epigallocatechin gallate.
9/2015	Synergistic enhancement of anticancer effects on numerous human cancer cell lines treated with the combination of EGCG, other green tea catechins, and anticancer compounds.
3/2015	Primary cancer prevention by green tea, and tertiary cancer prevention by the combination of green tea catechins and anticancer compounds.
10/2013	Tumor promoters: from chemicals to inflammatory proteins.
6/2002	Lung cancer prevention with (-)-epigallocatechin gallate using monitoring by heterogeneous nuclear ribonucleoprotein B1.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Eisaburo Sueoka Research Topics

Disease

33	Neoplasms (Cancer) 09/2023 - 06/2002
18	Lung Neoplasms (Lung Cancer) 01/2020 - 06/2002
7	Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated) 08/2023 - 03/2011
5	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2017 - 04/2003
4	Carcinogenesis 01/2021 - 08/2003
4	Adenocarcinoma of Lung 06/2017 - 04/2003
4	Adenocarcinoma 09/2012 - 04/2003
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 09/2023 - 01/2015
3	Neoplasm Metastasis (Metastasis) 01/2020 - 01/2014
3	Leukemia 12/2018 - 01/2015
3	Adenoma (Adenomas) 02/2018 - 03/2015
2	Pancreatic Neoplasms (Pancreatic Cancer) 09/2023 - 05/2023
2	Breast Neoplasms (Breast Cancer) 09/2023 - 12/2018
2	Inflammation (Inflammations) 09/2023 - 10/2013
2	Hepatocellular Carcinoma (Hepatoma) 09/2023 - 12/2002
2	Colorectal Neoplasms (Colorectal Cancer) 09/2023 - 05/2019
2	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 09/2023 - 12/2014
2	Lymphoma (Lymphomas) 08/2023 - 11/2011
2	Fatty Liver 01/2021 - 01/2016
2	Hypoxia (Hypoxemia) 01/2018 - 01/2015
2	Multiple Sclerosis 04/2008 - 12/2004
2	Tropical Spastic Paraparesis (Tropical Spastic Paraplegia) 04/2008 - 12/2004
1	Prostatic Neoplasms (Prostate Cancer) 09/2023
1	Circulating Neoplastic Cells 09/2023
1	T-Cell Leukemia (Leukemia, T Cell) 08/2023
1	Thrombosis (Thrombus) 05/2023
1	Venous Thromboembolism 05/2023
1	Stomach Neoplasms (Stomach Cancer) 01/2021
1	Disease Progression 01/2021
1	Glioma (Gliomas) 05/2019
1	Bronchiolitis Obliterans Syndrome 03/2019
1	Alzheimer Disease (Alzheimer's Disease) 12/2018
1	Neutropenia 10/2018
1	Thrombocytopenia (Thrombopenia) 10/2018
1	Experimental Melanoma 02/2018
1	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2018
1	Exanthema (Rash) 01/2018
1	Lymphadenopathy 01/2017
1	Anemia 01/2016

Drug/Important Bio-Agent (IBA)

13	Proteins (Proteins, Gene)FDA Link 09/2023 - 06/2002
10	Tyrosine Kinase InhibitorsIBA 01/2023 - 02/2007
9	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 08/2005
8	Messenger RNA (mRNA)IBA 02/2018 - 06/2002
8	Heterogeneous-Nuclear Ribonucleoproteins (Informatin)IBA 11/2008 - 06/2002
7	ErbB Receptors (EGF Receptor)IBA 09/2023 - 06/2008
6	TeaIBA 02/2018 - 06/2002
6	hnRNP A2IBA 11/2008 - 06/2002
5	Biomarkers (Surrogate Marker)IBA 08/2023 - 06/2002
5	RNA-Binding Proteins (RNA-Binding Protein)IBA 11/2008 - 04/2003
4	CarcinogensIBA 09/2023 - 10/2013
4	Okadaic AcidIBA 09/2023 - 10/2013
4	epigallocatechin gallate (epigallocatechin-3-gallate)IBA 02/2018 - 06/2002
3	Cell-Free Nucleic AcidsIBA 08/2023 - 04/2005
3	Interleukin-2 Receptors (IL 2 Receptor)IBA 01/2021 - 01/2017
3	AntibodiesIBA 04/2008 - 09/2004
2	Histones (Histone)IBA 01/2023 - 01/2018
2	mogamulizumabIBA 02/2019 - 01/2018
2	Phosphoprotein Phosphatases (Phosphatases, Protein)IBA 12/2018 - 10/2013
2	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 06/2017 - 01/2012
2	TabletsIBA 09/2015 - 03/2015
2	Dexamethasone (Maxidex)FDA LinkGeneric 11/2011 - 08/2011
2	RNA (Ribonucleic Acid)IBA 11/2008 - 04/2005
2	Gefitinib (Iressa)FDA Link 06/2008 - 02/2007
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 09/2023
1	Transcription Factors (Transcription Factor)IBA 09/2023
1	FibrinIBA 05/2023
1	pertuzumabIBA 01/2023
1	AfatinibIBA 01/2023
1	Lapatinib (GW572016)FDA Link 01/2023
1	Trastuzumab (Herceptin)FDA Link 01/2023
1	Heme (Haem)IBA 01/2022
1	Cell Surface ReceptorsIBA 01/2021
1	Serum AlbuminIBA 01/2021
1	Cell Adhesion Molecule-1IBA 01/2021
1	Immunoglobulins (Immunoglobulin)IBA 01/2021
1	ImmunosorbentsIBA 01/2021
1	NucleolinIBA 01/2021
1	Conditioned Culture MediaIBA 01/2020
1	LigandsIBA 05/2019
1	TankyrasesIBA 05/2019
1	Hypoglycemic Agents (Hypoglycemics)IBA 05/2019
1	Fingolimod Hydrochloride (FTY720)FDA Link 12/2018
1	Protein Phosphatase 2 (Protein Phosphatase 2A)IBA 12/2018
1	Anticarcinogenic AgentsIBA 12/2018
1	antineoplaston A10 (A 10)IBA 02/2018
1	Bleomycin (Blenoxane)FDA LinkGeneric 01/2018
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2018
1	Caspase 3 (Caspase-3)IBA 01/2018
1	9,10-Dimethyl-1,2-benzanthraceneIBA 12/2017
1	Discoidin Domain ReceptorsIBA 01/2017
1	Discoidin Domain Receptor 2IBA 01/2017
1	hydroxyethyl methacrylate (HEMA)IBA 01/2016
1	TOR Serine-Threonine KinasesIBA 01/2016
1	Sirolimus (Rapamycin)FDA Link 01/2016
1	Mechanistic Target of Rapamycin Complex 1IBA 01/2016

Therapy/Procedure

5	Therapeutics 09/2023 - 09/2004
5	Drug Therapy (Chemotherapy) 01/2021 - 09/2007
3	Hematopoietic Stem Cell Transplantation 03/2019 - 12/2015
2	Precision Medicine 01/2023 - 05/2019
1	Radiotherapy 09/2023